Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Jeffrey A. Bluestone; Jane H. Buckner; Mark Fitch; Stephen E. Gitelman; Shipra Gupta; Marc Hellerstein; Kevan C. Herold; Angela Lares; Michael R. F. Lee; Kelvin Li; Weihong Liu; S. Alice Long; Lisa M. Masiello; Vinh Nguyen; Amy Putnam; Mary Rieck; Peter H. Sayre; Qizhi Tang

doi:10.1126/scitranslmed.aad4134

Related publications

Article2017

Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants

Sindhu Chandran, Qizhi Tang, Minnie Sarwal, Zoltán Lászik, Amy Putnam, Kyoungtae Lee, Joey Leung, Nguyễn Hoàng Việt, Tara K. Sigdel, Erica Tavares, Joshua Yang, Marc Hellerstein, Mark Fitch, Jeffrey A. Bluestone, Flavio Vincenti

Article2024

Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

Peng Liu, Liwei Zhao, Guido Guido Kroemer, Oliver Kepp

Article2007

NK Cells Lyse T Regulatory Cells in Human Infection with An Intracellular Pathogen (B167)

Saptarshi Roy, Peter J Barnes, Ankita Garg, Shin‐Hwar Wu, S Weis, P Rajavelu, David Cosman, Ramakrishna Vankayalapati

Article2013

Evaluation of <i>in vivo</i> T cell kinetics: use of heavy isotope labelling in type 1 diabetes

Jenna Bollyky, S. Alice Long, Mark Fitch, Paul L. Bollyky, Mary Rieck, Rebecca Rogers, Peter L. Samuels, Srinath Sanda, Jane H. Buckner, Marc Hellerstein, Carla J. Greenbaum

Article2017

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

Carole Fournier, François Martin, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi, Lionel Apétoh